13433
document
The effects of enterostatin intake on food intake and energy expenditure . Enterostatin ( ENT ) has been found to inhibit food intake and selectively inhibit fat intake in rats . Both peripheral and central mechanisms have been proposed . It also has been suggested that ENT may increase thermogenesis . The present study investigated the effects of oral ENT administration on food intake , energy expenditure and body weight in subjects with a preference for a high-fat diet . In a double-blind , placebo-controlled , randomized and crossover design , nine female and three male healthy subjects ( age 34 ( sd 11 ) years , BMI 24.5 ( sd 2.5 ) kg/m ( 2 ) ) with a preference for a high-fat diet ingested ENT ( 3 x 15 mg/d ) or placebo ( PLA ) while consuming a high-fat diet ad libitum for 4 d. Eight subjects ended each intervention with a 36 h stay in the respiration chamber , continuing the diet and treatment . Body-weight loss was significant ( ENT 0.8 ( se 0.3 ) kg , P < 0.05 ; PLA 1.3 ( se 0.3 ) kg , P < 0.001 ) , but not different between treatments . There was no difference between treatments in total energy intake ( ENT 37.1 ( se 2.6 ) , PLA 35.9 ( se 3.2 ) MJ ) , macronutrient composition , hunger , satiety and hedonic scores during the 4 d high-fat diet . Energy expenditure ( 24 h ) ( ENT 9.6 ( se 0.4 ) , PLA 9.5 ( se 0.4 ) MJ ) , sleeping and resting metabolic rate , diet-induced thermogenesis , activity-induced energy expenditure and 24 h RQ ( ENT 0.77 ( se 0.01 ) , PLA 0.77 ( se 0.01 ) ) were similar for both treatments . We conclude that oral ENT administration did not affect food intake , energy expenditure or body weight in subjects with a preference for a high-fat diet experiencing a negative energy and fat balance .
13434
Intervention_Pharmacological
enterostatin intake
13435
Intervention_Pharmacological
Enterostatin ( ENT )
13436
Intervention_Pharmacological
ENT
13437
Intervention_Pharmacological
ENT
13438
Intervention_Control
placebo-controlled
13439
Intervention_Pharmacological
high-fat diet ingested ENT
13440
Intervention_Control
placebo ( PLA )
13441
Intervention_Pharmacological
consuming a high-fat diet ad libitum
13442
Intervention_Pharmacological
ENT
13443
Intervention_Control
PLA
13444
Intervention_Pharmacological
ENT
13445
Intervention_Control
PLA
13446
Intervention_Pharmacological
ENT
13447
Intervention_Control
PLA
13448
Intervention_Pharmacological
ENT
13449
Intervention_Control
PLA
13450
Intervention_Pharmacological
ENT
13451
Outcome_Physical
food intake and energy expenditure .
13452
Outcome_Mental
food intake
13453
Outcome_Other
energy expenditure
13454
Outcome_Physical
body weight
13455
Outcome_Physical
Body-weight loss
13456
Outcome_Physical
total energy intake
13457
Outcome_Physical
macronutrient composition , hunger , satiety and hedonic scores
13458
Outcome_Other
Energy expenditure
13459
Outcome_Physical
sleeping and resting metabolic rate , diet-induced thermogenesis , activity-induced energy expenditure and 24 h RQ
13460
Outcome_Mental
food intake
13461
Outcome_Other
energy expenditure
13462
Outcome_Physical
body weight
13463
Participant_Condition
fat intake
13464
Participant_Condition
rats
13465
Participant_Condition
subjects with a preference for a high-fat diet .
13466
Participant_Sample-size
nine
13467
Participant_Sex
female
13468
Participant_Sample-size
three
13469
Participant_Sex
male
13470
Participant_Age
age 34 ( sd 11 )